Trial Profile
Phase II piolot study of hyper-CVAD [cyclophosphamide + vincristine + doxorubicin + dexamethasone] plus rituximab for previously untreated mantle cell lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2010
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 12 May 2010 Actual end date (1 Mar 2010) added as reported by ClinicalTrials.gov record.
- 12 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2010 Planned end date changed from 1 Dec 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.